Method for preparing impurity oxalate of intermediate condensation compound of pradaxa
By reacting p-aminobenzamidine dihydrochloride with n-hexyl chloroformate, combined with oxalic acid dihydrate, the impurity oxalate of the dabigatran etexilate intermediate condensate is prepared, solving the unknown problem in the dabigatran etexilate intermediate condensate. The problem of low impurity purity has been solved, and high-purity preparation and technological progress have been achieved.
Patent Information
- Application Number
- CN201510862480.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2015-11-30
- Publication Date
- 2016-02-24
- Estimated Expiration
- 2035-11-30
AI Technical Summary
In the preparation process of dabigatran etexilate intermediate condensate, there are a large number of unknown impurities, resulting in low purity and affecting product quality and technological progress.
The impurity oxalate of dabigatran etexilate intermediate condensate is prepared by reacting p-aminobenzamidine dihydrochloride with n-hexyl chloroformate, combined with oxalic acid dihydrate, using specific reaction steps and conditions, including in 18 Add p-aminobenzamidine dihydrochloride solid in batches at -22°C, control the reaction time and temperature, then add water and acetone to dissolve, cool down to crystallize, filter and dry.
The high-purity preparation of the impurity oxalate, the condensation product of dabigatran etexilate etexilate, was achieved. The HPLC content was greater than 98%, and the yield reached more than 46.5%, which promoted the impurity research and synthesis technology progress of dabigatran etexilate etexilate.